Opinion

Video

IL-13–Targeting Agents in Atopic dermatitis

Panelists discuss the differences between the 3 FDA-approved IL-13–targeting agents for atopic dermatitis (AD)—dupilumab, tralokinumab, and lebrikizumab—and how these differences in their mechanisms of action might impact their effectiveness in targeting the disease and addressing various patient needs.

Video content above is prompted by the following:

  • There are 3 IL-13–targeting agents that are FDA-approved for treatment of AD (dupilumab, tralokinumab, and lebrikizumab).
  • How do they differ from each other?
  • How might these differences impact how these drugs target the disease?
Related Videos
Safety Profile, Accessibility of Tapinarof Cream for Atopic Dermatitis, with Adelaide Hebert, MD
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
Sobia Laique, MD | Credit: Cleveland Clinic
Sobia Laique, MD | Credit: Cleveland Clinic
What is the Global Lung Function Initiative and Its Purpose for Lung Function Testing?
Greg A. Sachs, MD I Credit: Regenstrief Institute
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.